Integrin αvβ3 upregulates integrin-linked kinase expression in human ovarian cancer cells via enhancement of ILK gene transcription

Journal of Cellular Physiology

Volumn 220, Issue 2, 2009, Pages 367-375

  Lössner, Daniela ^a   Abou Ajram, Claudia ^a   Benge, Anke ^a   Aumercier, Marc ^b   Schmitt, Manfred ^a   Reuning, Ute ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTEGRIN LINKED KINASE; PROTEIN P53; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR ETS; TRANSCRIPTION FACTOR REL; VITRONECTIN; VITRONECTIN RECEPTOR; INTEGRIN-LINKED KINASE; PROTEIN SERINE THREONINE KINASE;

ARTICLE; CANCER CELL CULTURE; CELL ADHESION; CELL SURFACE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DNA BINDING; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME LOCALIZATION; FEMALE; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; OVARY CANCER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; OVARY TUMOR; PATHOLOGY; SITE DIRECTED MUTAGENESIS; TUMOR CELL LINE;

ANIMALS; BASE SEQUENCE; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTEGRIN ALPHAVBETA3; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; OVARIAN NEOPLASMS; PROMOTER REGIONS, GENETIC; PROTEIN-SERINE-THREONINE KINASES; TRANSCRIPTION, GENETIC;

EID: 67649304830     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21774     Document Type: Article

References (46)

1. Ahmed N, Riley C, Oliva K, Sturr E, Rice GE, Quinn MA. 2003. Integrin-linked kinase expression increases with ovarian tumor grade and is sustained by peritoneal tumor fluid. J Pathol 201:229-237.
2. Ahmed N, Oliva K, Rice GE, Quinn MA. 2004. Cell-free 59 kDa immunoreactive integrinlinked kinase: A novel marker for ovarian carcinoma. Clin Cancer Res 10:2415-2420.
3. Barreuther MF, Grabel LB. 1996. The role of phosphorylation in modulating b1-integrin localization. Exp Cell Res 222:10-15.
4. Beck V, Herold H, Benge A, Luber B, Hutzler P, Tschesche H, Kessler H, Schmitt M, Geppert HG, Reuning U. 2005. ADAM15 decreases integrin avb3/vitronectin-mediated ovarian cancer cell adhesion and motility in an RGD-dependent fashion. Int J Biochem Cell Biol 37:590-603.
5. Carreiras F, Denoux Y, Staedel C, Lehmann M, Gaudochon P. 1996. Expression and localization of av integrins and their ligand vitronectin in normal ovarian epithelium and in ovarian carcinoma. Gynecol Oncol 62:260-267.
6. Carreiras F, Cruet S, Staedel C, Sichel F, Gaudochon P. 1999. Human ovarian adenocarcinoma cells synthesize vitronectin and use it to organize their adhesion. Gynecol Oncol 72:312-322.
7. Chinenov Y, Kerppola TK. 2001. Close encounters of many kinds: Fos-Jun interactions that mediate transcription regulatory specificity. Oncogene 20:2438-2452.
8. Davidson B, Reich R, Goldberg I, Gotlieb WH, Kopolovic J, Berner A, Ben-Baruch G, Bryne M, Nesland JM. 2001. Ets-1 messenger RNA expression is a novel marker of poor survival in ovarian carcinoma. Clin Cancer Res 7:551-557.
9. Dedhar S. 2000. Cell/substrate interactions and signaling through ILK. Curr Opin Cell Biol 12:250-256.
10. Felding-Haberman B. 2003. Integrin adhesion receptors in tumor metastasis. Clin Exp Metas 20:203-213.
11. Giamas G, Stebbing J, Vorgias CE, Knippschild U. 2007. Protein kinases as targets for cancer treatment. Pharmacogenomics 8:1005-1016.
12. Hannigan GE, Leung-Hagesteijn C, Fitz-Gibbon L, Coppolino MG, Radeva G, Filmus J, Bell JC, Dedhar S. 1996. Regulation of cell adhesion and anchorage-dependent growth by a new bβ1-integrin-linked protein kinase. Nature 379:91-96.
13. Hannigan GE, Bayani J,Weksberg R, Beatty B, Pandita A, Dedhar S, Squire J. 1997. Mapping of the gene encoding the integrin-linked kinase, ILK, to human chromosome 11p15.5-p15.4. Genomics 42:177-179.
14. Hannigan G, Troussard AA, Dedhar S. 2005. Integrin-linked kinase. A cancer therapeutic target unique among its ILK. Nature Rev Cancer 5:51-63.
15. Hapke S, Kessler H, Arroyo de Prada N, Benge A, Schmitt M, Lengyel E, Reuning U. 2001. Integrin avb3/vitronectin interaction affects expression of the urokinase system in human ovarian cancer cells. J Biol Chem 276:26340-26348.
16. Hapke S, Kessler H, Luber B, Benge A, Hutzler P, Höfler H, Schmitt M, Reuning U. 2003. Ovarian cancer cell proliferation and motility is induced by engagement of integrin aαvbβ3/ vitronectin interaction. Biol Chem 384:1073-1083.
17. Heckmann D, Kessler H. 2007. Design and chemical synthesis of integrin ligands. Methods Enzymol 426:463-503.
18. Ho J, Benchimol S. 2003. Transcriptional repression mediated by the p53 tumour suppressor. Cell Death Diff 10:404-408.
19. Hsu T, Trojanowska M, Watson DK. 2004. Ets proteins in biological control and cancer. JCell Biochem 91:896-903.
20. Humphries MJ,McEwan PA, Barton SJ, Buckley PA, Bella J, Mould AP. 2003. Integrin structure: Heady advances in ligand binding, but activation still makes the knees wobble. Trends Biochem Sci 28:313-320.
21. Ito R, Oue N, Zhu X, Yoshida K, Nakayama H, Yokozaki H, Yasui W. 2003. Expression of integrin-linked kinase is closely correlated with invasion and metastasis of gastric carcinoma. Virchows Arch 442:118-123.
22. Kita D, Takino T, Nakada M, Takahashi T, Yamashita J, Sato H. 2001. Expression of dominantnegative form of Ets-1 suppresses fibronectin-stimulated cell adhesion and migration through down-regulation of integrin a5 expression in U251 glioma cell line. Cancer Res 61:7985-7991.
23. Liapis H, Adler L, Wick R, Rader J. 1997. Expression ofavb3 integrin is less frequent in ovarian epithelial tumors of low malignant potential in contrast to ovarian carcinomas. Hum Pathol 28:443-449.
24. Lössner D, Abou-Ajram C, Benge A, Reuning U. 2008. Integrinavb3mediates upregulation of epidermal growth-factor receptor expression and activity in human ovarian cancer cells. Int J Biochem Cell Biol 40:2746-2761.
25. Marinelli L, Lavecchia A, Gottschalk KE, Novellino E, Kessler H. 2003. Docking studies on aαvbβ3 integrin ligands: Pharmacophore refinement and implications for drug design. J Med Chem 46:4393-4404.
26. Melchior C, Kreis S, Janji B, Kieffer N. 2002. Promoter characterization and genomic organization of the gene encoding integrin-linked kinase 1. Biochim Biophys Acta 1575:117-122.
27. Möbus V, Gerharz CD, Press U, Moll R, Beck T, Mellin W, Pollow K, Knapstein PG, Kreienberg R. 1992. Morphological, immunohistochemical and biochemical characterization of 6 newly established human ovarian carcinoma cell lines. Int J Cancer 52:76-84.
28. Oikawa T. 2004. Ets transcription factors: Possible targets for cancer therapy. Cancer Sci 95:626-633.
29. Persad S, Dedhar S. 2003. The role of integrin-linked kinase (ILK) in cancer progression. Cancer Metas Rev 22:375-384.
30. Petrovics G, Liu A, Shaheduzzaman S, Furusato B, Sun C, Chen Y, Nau M, Ravindranath L, Chen Y, Dobi A, Srikantan V, Sesterhenn IA, McLeod DG, Vahey M, Moul JW, Srivastava S. 2005. Frequent overexpression of Ets-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 24:3847-3852.
31. Rippe RA, Lorenzen SI, Brenner DA, Breindl M. 1989. Regulatory elements in the 50-flanking region and the first intron contribute to transcriptional control of the mouse a1 type I collagen gene. Mol Cell Biol 9:2224-2227.
32. Sayeed A, Konduri SD, Liu W, Bansal S, Li F, Das GM. 2007. Estrogen receptor-a inhibits p53-mediated transcriptional repression: Implications for the regulation of apoptosis. Cancer Res 67:7746-7755.
33. Schwartz MA, Ginsberg MH. 2002. Networks and crosstalk: Integrin signaling spreads. Nat Cell Biol 4:E65-E68.
34. Scian MJ, Carchman EH, Mohanraj L, Stagliano KE, Anderson MA, Deb D, Crane BM, Kiyono T, Windle B,Deb SP,Deb S. 2007. Wild-type p53 and p73 negatively regulate expression of proliferation related genes. Oncogene 27:2583-2593.
35. Sementchenko VI, Watson DK. 2000. Ets target genes: Past, present, and future. Oncogene 19:6533-6548.
36. Seth A, Watson DK. 2005. Ets transcription factors and their emerging roles in human cancer. Eur J Cancer 41:2462-2478.
37. Sulyok GA, Gibson C, Goodman SL, Hölzemann G, Wiesner M, Kessler H. 2001. Solid-phase synthesis of a nonpeptide RGD mimetic library: New selective avb3 integrin antagonists. J Med Chem 44:1938-1950.
38. Supakar PC, Jung MH, Song CS, Chatterjee B, Roy AK. 1995. NF-kκB functions as a negative regulator for the rat androgen receptor gene and NF-kκB activity increases during the agedependent desensitization of the liver. J Biol Chem 270:837-842.
39. Troussard AA, Mawji NM, Ong C, Mui A, St-Arnaud R, Dedhar S. 2003. Conditional knockout of integrin-linked kinase demonstrates an essential role in protein kinase B/Akt activation. J Biol Chem 278:22374-22378.
40. Troussard AA, McDonald PC, Wederell ED, Mawji NM, Filipenko NR, Gelmon KA, Kucab JE, Dunn SE, Emerman JT, Bally MB, Dedhar S. 2006. Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival. Cancer Res 66:393-403.
41. Verger A, Duterque-Coquillaud M. 2002.When Ets transcription factors meet their partners. Bioessays 24:362-370.
42. White DE, Cardiff RD, Dedhar S, Muller WJ. 2001. Mammary epithelial-specific expression of the integrin-linked kinase (ILK) results in the induction ofmammary gland hyperplasias and tumors in transgenic mice. Oncogene 20:7064-7072.
43. Wu C, Dedhar S. 2001. Integrin-linked kinase (ILK) and its interactors: A new paradigm for the coupling of extracellular matrix to actin cytoskeleton and signaling complexes. J Cell Biol 155:505-510.
44. Yau CY, Wheeler JJ, Sutton KL, Hedley DW. 2005. Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xenografts. Cancer Res 65:1497-1504.
45. Yoganathan N, Yee A, Zhang Z, Leung D, Yan J, Fazli L, Kojic DL, Costello PC, Jabali M, Dedhar S, Sanghera J. 2002. Integrin-linked kinase, a promising cancer therapeutic target: Biochemical and biological properties. Pharmacol Therapeut 93:233-242.
46. Zhang M, Maass N, Magit D, Sager R. 1997. Transactivation through Ets and AP1 transcription sites determines the expression of the tumor-suppressing gene maspin1. Cell Growth Diff 8:179-186.